Recent News

CAR T-Cell Therapy Versus Previous Standard of Care for Refractory Aggressive LBCL

ESMO 2022: Novel Antibody-Drug Conjugate Under Study in B-Cell Lymphoma

ESMO 2022: Role of ctDNA in Chinese Patients With Diffuse Large B-Cell Lymphoma

Use of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma

ESMO 2022: Can Machine Learning–Based Model Predict DLBCL Subtypes From Whole-Slide Images?

Prognostic Model May Help to Identify Elderly Patients With DLBCL Suited for Chemotherapy

Adding Bortezomib to Standard Treatment in Resistant DLBCL: Final Results From Phase II Trial

Safety and Efficacy of Blinatumomab for Patients With High-Risk DLBCL

BRUIN MCL-321 Focuses on Pirtobrutinib in BTK Inhibitor–Naive Mantle Cell Lymphoma

Zanubrutinib Plus Rituximab: Effective Alternative to R-CHOP in Elderly Patients With DLBCL?

Outcomes After BTK Inhibition in Mantle Cell Lymphoma: View From the United States and Japan

FDA Accepts sBLA for Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Induction Regimens for Older Patients With Mantle Cell Lymphoma

Survey of Oncologists and Hematologists: Considerations in Third-Line Treatment of Follicular Lymphoma

MSI2: Is This RNA-Binding Protein a Potential Therapeutic Target in Mantle Cell Lymphoma?

Pan Pacific 2022: POLARIX Trial of Polatuzumab Vedotin–Based Regimen in DLBCL

Primary Mediastinal LBCL: Closer Look at the Genetic Landscape

Phase II FLUORO Study to Evaluate Obinutuzumab Plus Atezolizumab in Follicular Lymphoma

Pan Pacific 2022: Early-Phase Study of Pirtobrutinib in Mantle Cell Lymphoma

Potential New Paradigm in the Diagnosis of Pediatric-Type Follicular Lymphoma

Ongoing Trial Aims to Study Efineptakin Alfa After Tisagenlecleucel Therapy for LBCL

Update on Brexucabtagene Autoleucel in the Treatment of Resistant Mantle Cell Lymphoma

Comparison of Two Different Chemotherapy Regimens for High-Risk Burkitt Lymphoma

Genetic and Molecular Profiling of Primary Mediastinal LBCL Identifies Probable Pathogenesis

Measurable Residual Disease–Driven, Time-Limited Treatment of Indolent Mantle Cell Lymphoma

Axicabtagene Ciloleucel Outcomes in LBCL Stratified by Ethnicity and Race

Updated Trial Data on Tazemetostat-Based Regimen in Follicular Lymphoma

Priority Review Granted by FDA for Mosunetuzumab in Follicular Lymphoma

Phase III Study to Evaluate Tafasitamab-cxix–Based Therapy for Advanced B-Cell Lymphoma

ASCO 2022: Novel CAR T-Cell Therapy Targets CD20 in Treatment of B-Cell Malignancies

Lisocabtagene Maraleucel Approved by FDA in Second-Line Treatment of LBCL

ASCO 2022: Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Follicular Lymphoma

After CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma: What’s Next?

EHA 2022: Patient-Reported Outcomes With Lisocabtagene Maraleucel in LBCL

ASCO 2022: Influence of Racial Identity on Survival Outcomes in DLBCL

EHA 2022: Preliminary Data From PACIFIC Trial of Nivolumab Plus Brentuximab Vedotin in LBLC

EHA 2022: Fixed Duration of Bispecific Antibody Glofitamab in Resistant DLBCL

ASCO 2022: 3-Year Follow-Up From ZUMA-2 Trial of KTE-X19 in Resistant Mantle Cell Lymphoma

Utility of Routinely Collected Geriatric Assessment in Patients With DLBCL

ASCO 2022: Intermittent Dosing of Zandelisib in Resistant Follicular Lymphoma

FDA Withdraws Approval of Umbralisib for Treatment of Lymphomas Over Safety Concerns

ASCO 2022: Ibrutinib Plus Chemoimmunotherapy in Older Patients With Mantle Cell Lymphoma

FDA Grants Approval to Tisagenlecleucel for Treatment of Resistant Follicular Lymphoma

Risk of COVID-19 Breakthrough Infections in Vaccinated Patients With Hematologic Cancer

BTK Inhibitor Zanubrutinib Under Study in the Treatment of Resistant DLBCL

Phase II ZUMA-12 Trial Evaluates First-Line Use of Axicabtagene Ciloleucel in High-Risk LBCL

Predicting Remission With CAR T-Cell Therapy in Large B-Cell Lymphoma: Focus on FDG-PET Imaging

CD20-CD3 Bispecific Antibody Under Study in Resistant B-Cell Non-Hodgkin Lymphoma

Can ctDNA Analysis Be Used to Predict Outcomes in High-Risk DLBCL?

AKT Inhibitor Capivasertib Focus of Phase II Trial in B-Cell NHL

AACR 2022: Investigational BCL2 Inhibitors Demonstrate Varying Levels of Antilymphoma Activity

AACR 2022: Pharmacologic Attributes of Axicabtagene Ciloleucel and Therapeutic Index in Lymphoma

AACR 2022: Novel Microtubule-Targeting Agent Demonstrates Antilymphoma Activity

AACR 2022: Can BCL2 Family Protein Dephosphorylation Resensitize Venetoclax-Induced Apoptosis?

AACR 2022: Impact of PRMT5 Inhibition on BH3 Mimetic Sensitivity in Mantle Cell Lymphoma

AACR 2022: Predicting Response/Resistance to Brexucabtagene Autoleucel in Mantle Cell Lymphoma

AACR 2022: Can Decitabine Sensitize DLBCL Cells to Venetoclax?

Adding EP4 Receptor Agonists to CD20 Antigen Therapy in B-Cell Malignancies

Axicabtagene Ciloleucel Receives FDA Approval in Large B-Cell Lymphoma